Compare NetEase Inc (NTES) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs TransMedics Group Inc — how do they compare? NetEase Inc trades at $116.73 (market cap $76.64B), while TransMedics Group Inc trades at $88.6 (market cap $3.12B). The key difference: NetEase Inc is far larger — about 24.6× TransMedics Group Inc's market cap, and NetEase Inc pays a 2.46% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NTES | TMDX | |
|---|---|---|
Market Cap | $76.64B | $3.12B |
Sector | Media | Technology |
52-Week High | $159.34 | $150.42 |
52-Week Low | $109.26 | $61.99 |
Enterprise Value | $52.38B | $3.52B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of $4.4 billion, up 8% year-over-year, though EPS missed expectations. Strong fundamentals include a net income margin of 27.88% and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights focus on international expansion and AI investments.
Outlook remains mixed: analyst consensus is strongly bullish (82% buy ratings), but technicals suggest near-term pressure. Key opportunities include dividend growth and global gaming hits; risks involve earnings volatility and competitive pressures in the Chinese tech sector. The stock's valuation at a P/E of 15.92 offers room for upside if execution improves.
TransMedics Group (TMDX) trades at $88.27, down 1.9% over 24 hours, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 revenue of $605.49M and net income of $190.29M, though 2026 projections show margin pressure. Recent news highlights investigations into fiduciary duties by directors, alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The outlook is cautiously optimistic, supported by analyst consensus favoring Buy ratings and a $99.57 price target, implying potential upside. Key risks include ongoing legal scrutiny, execution challenges from heavy investments, and declining profit margins. Investors should weigh robust revenue growth against these headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
